Hypertension and nephrology

[ACEi or ARB? What are the results of the comparative analysis?]

BENCZÚR Béla

OCTOBER 20, 2017

Hypertension and nephrology - 2017;21(05)

[Angiotensin-converting enzyme inhibitors (ACEis) and angiotensin receptor blockers (ARBs) are treatment options for patients with cardiovascular disease (CVD) or those with cardiovascular risk factors. The comparative efficacy and safety of ACEis and ARBs have been much debated. To compare the benefits of angiotensin-converting enzyme inhibitors (ACEis) and angiotensin receptor blockers (ARBs) in patients without heart failure a metaanalysis was carried out based on 254.301 subjects of 106 randomised trials. Meta-analysis included randomized trials of ACEis and ARBs compared with placebo or active controls and corroborated with head-to-head trials of ARBs vs ACEis. According to placebo controlled studies ACEis but not ARBs reduced all-cause mortality, cardiovascular mortality and MI. It seems that ACEis are more effective than ARBs. But this is only true if we take into account the trials before 2000. The analysis restricted to trials published after 2000 revealed similar outcomes with ACEis vs placebo and ARBs vs placebo. Head-to-head comparison trials of ARBs vs ACEis exhibited no difference in outcomes. The underlying causes and details are explained in this review.]

COMMENTS

0 comments

Further articles in this publication

Hypertension and nephrology

[The Extent of Overweight and Obesity in Children and Adolescents According to Statistics. A Global Overview]

KÉKES Ede

Hypertension and nephrology

[A Letter to Our Readers]

KÉKES Ede

Hypertension and nephrology

[A New Approach to Polypill Strategy: Quadpill Administration in the Initial Therapy of Hypertension The Quadpill Study]

VÁRALLYAY Zoltán

Hypertension and nephrology

[A Letter to our Colleagues]

JÁRAI Zoltán

Hypertension and nephrology

[Report on the 25th Jubilee Congress of the Hungarian Society of Hypertension]

NEMCSIK János, JÁRAI Zoltán

All articles in the issue

Related contents

Lege Artis Medicinae

[Cardiovascular prevention]

ZÁMOLYI Károly

[Cardiovascular diseases are the leading causes of morbidity and mortality worldwide. Before the appearance of overt symptoms of various diseases, a silent, progressive condition exists. The main goal of prevention guidelines is to reduce the incidence of first and recurrent clinical events, which include coronary heart disease, ischaemic stroke and peripheral artery disease. Modification of risk factors has been proved to reduce cardiovascular mortality and morbidity, especially in patients with a high risk. By reducing the risk of substantial cardiovascular events it is possible to ameliorate premature disability, prolong survival and improve quality of life. We would like to emphasize the importance of lifestyle changes, the management of major cardiovascular risk factors and the use of various prophylactic drug therapies in the prevention of cardiovascular diseases. Medical intervention strategies for high-risk patients include the use of acetilsalycilic acid, statin, beta-blocker, ACE-inhibitor and anticoagulant for the treatment of any disease where the use of such drugs has been supported by evidence. The specific preventive effect of a drug is considered to be verified if the drug significantly reduced the incidence of pirmary vascular outcomes, beyond its primary pharmacodynamic effect, or if it is likely to have such an effect according to adequately powered metaanalyses.]

Lege Artis Medicinae

[Cardiovascular diseaes and the kidney]

PRÉDA István

[From pathophysiological point of view, the kidney is an integral part of the cardiovascular system. Renal diseases adversely affect the cardiac functions, and disturbances of the cardiovascular system affect adversely renal functions, causing either the decrease of left ventricular functions or manifesting in overt chronic heart failure. Regarding the cardiac manifestations of renal diseases, characteristic features are the symptoms of left ventricular volume and pressure overload, the metabolic effects of the ”uremic toxins” and the frequent infections associated with dialysis and compromised immunologic state, the secunder hyperparathyreosis, as well as the associated conditions like hypertension, diabetes mellitus and coronary atherosclerosis. All these can be the explanation for the frequent cardiovascular death of chronic kidney disease patients. It also stresses the outstanding importance of the decrease of cardiovascular hazard of chronic renal disease patients. The strategy should comprise of an adequate antihypertensive treatment (ACE-inhibitor, AT-II blocking and calcium antagonist), strong antidiabetic control of diabetic patients and the adequate treatment of dyslipidaemia (if exists), as well as antithrombotic aspirin treatment.]

LAM Extra for General Practicioners

[EFFECT OF BETA BLOCKERS IN HYPERTENSION, ISCHAEMIC HEART DISEASE, HEART FAILURE AND METABOLIC SYNDROME]

BENCZÚR Béla

[Beta-blockers are among the most widely used drugs for the treatment of cardiovascular diseases. In the mid-90’s, these drugs were recommended as first-line therapies of hypertension. With the introduction of new drugs, the list of first-choice drugs has been extended. The results of recently published major hypertension trials, which compared conventional agents (beta blockers and/or diuretics) with newer agents (angiotensin converting enzyme inhibitors, Caantagonists, angiotensin receptor blockers), raised concerns regarding the role of beta blockers in cardiovascular primary prevention. Subsequently, a metaanalysis of 13 trials has shown that compared with other drug types, beta-blocker therapy is less beneficial in patients with hypertension who do not have heart disease. Nevertheless, in cardiovascular indications other than hypertension (acute myocardial infarction, heart failure and arrhythmias), betablockers retain their dominant position.]

Lege Artis Medicinae

[How diabetogenic is statin therapy?]

CSÁSZÁR Albert

[According to the latest guidelines, the goal in cardiovascular prevention is to achieve an LDL-cholesterol level no higher than 1.8 mmol/l in the high risk and extra high risk groups. According to international recommendations, statin should be used at the highest tolerable dose rather than any combination treatments. In a number of cases, higher doses are associated with increased side effects, which rarely affect liver enzymes and CK-parameters. A metaanalysis published in 2011 made it clear that higher statin doses compared with low-medium doses can increase the occurence of newonset diabetes by about 12%. This is presumably a class effect, which is not significant according to the guidelines, and which is much lesser than the benefits of this therapy in the prevention of cardiovascular events, thus, it obviously does not question the justification of statin treatment. However, the observed association implies that during statin therapy of nondiabetic patients, blood glucose control should be performed every year, and, if needed, an oral glucose tolerance test should be performed to detect the potential development of diabetes.]

Hypertension and nephrology

[Results of ATTENTION study]

LÉGRÁDY Péter, ÁBRAHÁM György

[In the ATTENTION (Using of ARB and sTaTin basEd iNdividualized Treatments in Hungarian patients In the light Of New CV prevention guidelines) trial’s ARB arm 9996 treated hypertensive patients were enrolled. Based on the results in the medical practice, the choice of the first ARB has a significant impact on the further antihypertensive therapy. Losartan, telmisartan and valsartan are all suitable for reaching the goal blood pressure. If necessary, doctors will not change the composition but the dose or use a diuretic supplement (resistant hypertension, older age etc.). Overall a telmisartan preference was observed in the study.]